ProCE Banner Activity

CARTITUDE-1 Phase Ib/II Study of Ciltacabtagene Autoleucel in Patients With R/R MM: 2-Yr Update

Slideset Download
Conference Coverage
A median of ~2 years of follow-up of the CARTITUDE-1 trial showed durable and deepening responses with cilta-cel in patents with relapsed/refractory multiple myeloma.

Released: December 16, 2021

Expiration: December 15, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation